Form SC 13G/A Sarepta Therapeutics, Filed by: SUSQUEHANNA SECURITIES
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Sarepta Therapeutics (SRPT) U.K.-Specific Hold Concerns 'Overblown' - William Blair
February 9, 2018 11:51 AM ESTWilliam Blair analyst Tim Lugo came out to deafened Sarepta Therapeutics (NASDAQ: SRPT) following reports of a U.K.-specific hold on further dosing of patients enrolled in Sareptas global Phase III ESSENCE trial of golodirsen.
Lugo sees the concerns as "overblown".
To wit... "We see todays roughly 6% sell-off... More
